A Randomized, Double-Blind, Placebo- Controlled, Multicentre Phase III Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain.
- Year: 2007
- Type: Pharmaceutical - Pain
- Phase: III
- Indication: Pain - General